Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Liposomal doxorubicin is a chemotherapy drug, which is administered intravenously to treat AIDS-related Kaposi's sarcoma, breast cancer, ovarian cancer, and other solid tumors. Liposome drug delivery systems are able to modify pharmacokinetics and bio-distribution of cytostatic agents, it increases the concentration of the drug released to neoplastic tissue and reduces the exposure of normal tissue with the drug. This drug is a type of anthracycline antitumor antibiotic, also known as Doxil and doxorubicin hydrochloride liposome. Dosage of doxorubicin hydrochloride liposome depends on several factors including, height and weight, general health or other health problems, and the type of cancer such as ovarian cancer, AIDS-related kaposi's sarcoma, and multiple myeloma.

The U.S. liposomal doxorubicin market is estimated to be valued at US$ 140.0 Million in 2020 and is expected to reach US$ 192.9 Million by 2027, exhibiting a CAGR of 4.7% over the forecast period (2020-2027).

Figure 1. U.S. Liposomal Doxorubicin Market Value (US$ Million) Analysis and Forecast and Y-o-Y Growth (%), 2020

U.S. Liposomal Doxorubicin  | Coherent Market Insights

The increasing approval of generic products is expected to drive the U.S. liposomal doxorubicin market growth

The increasing approval of generic products of liposomal doxorubicin from regulatory authorities is expected to boost demand for liposomal doxorubicin and this is further expected to drive growth of the U.S. liposomal doxorubicin market. For instance, in March 2017, Dr. Reddy’s Laboratories Ltd announced that it received the U.S. Food Drug and Administration approval to launch doxorubicin hydrochloride liposome injection in the U.S., which is a generic version of Janssen Products’ Doxil (doxorubicin hydrochloride liposome injection). Doxorubicin hydrochloride liposome injection is indicated for the treatment of ovarian cancer and administered intravenously in the patients.

request-sample

U.S. Liposomal Doxorubicin Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 140.0 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 4.7% 2027 Value Projection: US$ 192.9 Mn
Geographies covered:
  • U.S.
Segments covered:
  • By Drug Type: Branded, Generic
  • By Cancer Type: Ovarian Cancer, AIDS-related Kaposi’s Sarcoma, Multiple Myeloma, Others
  • By States: California, Texas, Florida, New York, Pennsylvania, Illinois, Ohio, Georgia, North Carolina, Michigan, New Jersey, Virginia, Washington, Arizona, Others
Companies covered:

Johnson & Johnson, Baxter International Inc., Sun Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories, Inc.

Growth Drivers:
  • Increasing prevalence of cancer
  • Increasing approvals of generic products
Restraints & Challenges:
  • Side effects associated with liposomal doxorubicin
  • COVID-19 impact on liposomal doxorubicin retail sales

Figure 2. U.S. Liposomal Doxorubicin Market Share (%), By Cancer Type 2020

U.S. Liposomal Doxorubicin  | Coherent Market Insights

U.S. Liposomal Doxorubicin Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. The private healthcare sector is one of the sectors, which has been majorly impacted by the pandemic. The lockdowns in various countries have created an economic burden on the private healthcare sector. Healthcare providers are facing challenges with regards to manpower, equipment, consumables, and other resources to ensure safety of patients with other diseases, and declining outpatients’ visits, among others. Moreover, the pandemic has negatively impacted the development, production, and supply of drugs, and affected growth of the liposomal doxorubicin market and healthcare segment of various companies across the globe. This has led to closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of products. Thus, the Covid-19 pandemic is expected to slightly disrupt the R&D activities of healthcare sector as well as in the liposomal doxorubicin market.

U.S. Liposomal Doxorubicin Market: Restraint

Some side effects associated with liposomal doxorubicin drug is expected to hamper the growth of market. The side effects include increased risk of infection, breathlessness and pale complexion, bruising, bleeding gums and nosebleeds, tiredness and weakness (fatigue) during and after treatment, redness, soreness, and peeling of the hands and feet, loss of weight, and diarrhea among others.

Key Players

Major players operating in the U.S. liposomal doxorubicin market include Johnson & Johnson, Baxter International Inc., Sun Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories, Inc.

Liposomal doxorubicin is a chemotherapy drug, which is administered intravenously to treat AIDS-related Kaposi's sarcoma, breast cancer, ovarian cancer, and other solid tumors. Doxorubicin acts by blocking an enzyme called topoisomerase 2 that cancer cells need in order to divide and grow. Liposomal delivery of doxorubicin HCL (Hydrochloride) improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. Some side effects of using Doxil or doxorubicin hydrochloride liposome include low blood counts, hand-to-foot syndrome (palmar-plantar erythrodysesthesia), mouth sores, infusion-related side effects: shortness of breath, facial swelling, headache, back pain, flushing, tightness in the chest and throat, and/or low blood pressure.

Market Dynamics

The increasing prevalence of cancer is expected to drive demand for liposomal doxorubicin for treatment of the disease and aid in growth of the U.S. liposomal doxorubicin market. For instance, according to the American Cancer Society, in 2017, cancer was the second most common cause of death in the U.S., and accounted for nearly one out of four deaths. Moreover, according to National Cancer Institute, in 2019, around 1.8 million people were diagnosed with cancer in the U.S., and around 276,480 women and 2,670 men were diagnosed with breast cancer.

Key features of the study:

  • This report provides in-depth analysis of the U.S. liposomal doxorubicin market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the U.S. liposomal doxorubicin market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
  • Key companies covered as a part of this study include Johnson & Johnson, Baxter International Inc., Sun Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The U.S. liposomal doxorubicin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. liposomal doxorubicin market

Detailed Segmentation:

  • U.S. Liposomal Doxorubicin Market, By Drug Type:
    • Branded
    • Generic
  • U.S. Liposomal Doxorubicin Market, By Cancer Type:
    • Ovarian Cancer
      • AIDS-related Kaposi’s Sarcoma
      • Multiple Myeloma
      • Others
  • U.S. Liposomal Doxorubicin Market, By States:
    • California
    • Texas
    • Florida
    • New York
    • Pennsylvania
    • Illinois
    • Ohio
    • Georgia
    • North Carolina
    • Michigan
    • New Jersey
    • Virginia
    • Washington
    • Arizona
    • Others
  • Company Profiles
    • Johnson & Johnson*
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Baxter International Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Reddy’s Laboratories, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Type
      • Market Snapshot, By Cancer Type
      • Market Snapshot, By States
      • Market Opportunity Map
  3. U.S. Liposomal Doxorubicin Market Insights
    • Drivers
    • Restraints
    • Opportunity
    • Impact Analysis
    • Demand Analysis
    • Regulatory Scenario
    • Key Developments
    • PEST Analysis
    • Pricing Analysis
    • Competitive Snapshot
    • Pipeline Analysis
    • Major Distributors
    • Reimbursement Scenario
    • Epidemiology
    • Alternative Treatments
    • Liposomal Doxorubicin Import and Export
  4. Global Liposomal Doxorubicin Market Overview
    • Definition
    • Impact Analysis
    • Market Overview
    • Regional Share
    • S. & Global Market Comparison
  5. U.S. Liposomal Doxorubicin Market - Impact of Coronavirus (Covid-19) Pandemic
    • Impact on Supply Chain
    • Impact on Demand
  6. U.S. Liposomal Doxorubicin Market, By Drug Type, 2016 – 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027(%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Branded
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million)
    • Generic
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million)
  7. U.S. Liposomal Doxorubicin Market, By Cancer Type, 2016 – 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027(%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Ovarian Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million)
    • AIDS-related Kaposi’s Sarcoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million
    • Multiple Myeloma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million)
  8. U.S. Liposomal Doxorubicin Market, By States, 2016 – 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027(%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Country at Trends
    • California
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
    • Texas
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
    • Florida
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
    • New York
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
    • Pennsylvania
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
    • Illinois
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
    • Ohio
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
    • Georgia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
    • North Carolina
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
    • Michigan
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
    • New Jersey
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
    • Virginia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
    • Washington
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
    • Arizona
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
  9. Company Profiles
    • Johnson & Johnson
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Baxter International Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sun Pharmaceutical Industries Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Reddy’s Laboratories, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
  10. Section
    • Research Methodology
    • About us
    • Contacts

*Browse 9 market data tables and 29 figures on "liposomal doxorubicin market” – U.S. forecast to 2027

FAQgrowicon

Frequently Asked Questions

The U.S. liposomal doxorubicin market is estimated to be valued at US$ 140.0 Million in 2020 and is expected to increase to US$ 192.9 Million by 2027, exhibiting a CAGR of 4.7% over the forecast period.
The increasing prevalence of cancer and increasing approvals of generic liposomal doxorubicin products are expected to drive the market growth over the forecast period.
Generic is the leading drug type segment in the market.
Side effects associated with liposomal doxorubicin and COVID-19 impact on liposomal doxorubicin retail sales are the major factors that are restraining growth of the market.
Major players operating in the market include Johnson & Johnson, Baxter International Inc., Sun Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.